Theravance Biopharma, Inc.TBPHNASDAQ

Revenue (LTM)

$107M

+66.9% YoY

Net Income (LTM)

$106M

+287.7% YoY

Free Cash Flow

$-12M

Revenue CAGR (5Y)

+8.4%

Marginsimproving

FCF($0.0B)

Now profitable

Metric	Dec 21	Dec 22	Dec 23	Dec 24	Dec 25
Revenue	55	51↓7.2%	57↑11.8%	64↑12.1%	107↑66.9%
Gross Profit	-138	-12↑91.3%	17↑239.5%	64↑283.2%	0
Operating Income	-258	-92↑64.3%	-56↑39.1%	-47↑16.2%	-4↑92.3%
Net Income	-199	872↑537.3%	-55↓106.3%	-56↓2.2%	106↑287.7%
EBITDA	-233	-76↑67.3%	-52↑32.1%	-38↑25.5%	-4↑90.6%
EPS Diluted	-2.87	-1.26↑56.1%	-1.00↑20.6%	-1.15↓15.0%	2.06↑279.1%

Metric	Dec 21	Dec 22	Dec 23	Dec 24	Dec 25
Cash & Equivalents	90	298↑231.5%	40↓86.7%	38↓4.4%	0
Total Current Assets	250	353↑41.5%	134↓62.2%	161↑20.6%	418↑159.8%
Total Assets	375	607↑62.1%	382↓37.1%	354↓7.3%	486↑37.1%
Total Current Liabilities	59	29↓51.0%	25↓13.7%	32↑29.5%	38↑19.4%
Total Liabilities	713	166↓76.8%	169↑2.1%	179↑5.7%	0
Total Equity	-339	442↑230.5%	213↓51.8%	176↓17.6%	486↑176.6%
Total Debt	670	52↓92.2%	49↓5.8%	50↑1.3%	32↓36.3%
Net Debt	580	-246↓142.4%	10↑103.9%	12↑25.1%	32↑164.1%

Metric	Dec 20	Dec 21	Dec 22	Dec 23	Dec 24
Operating Cash Flow	-250	-208↑17.0%	-187↑10.0%	-27↑85.6%	-12↑57.3%
Capital Expenditure	-7	-3↑48.5%	-1↑83.2%	-2↓335.0%	-0↑86.7%
Free Cash Flow	-257	-211↑17.8%	-188↑11.2%	-29↑84.3%	-12↑59.8%
Stock-Based Comp	63	62↓1.5%	40↓36.0%	25↓36.1%	21↓15.7%
Net Change in Cash	23	8↓63.7%	208↑2350.7%	-259↓224.2%	-2↑99.3%

Values in millions except EPS · Ratios shown as percentages · Click any metric to drill down

Explore More

Filter and sort all 500 stocks

Today's biggest gainers and losers

Visual sector performance